US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

0.7999

+0.04265.63%

Volume:1.36M

Turnover:1.08M

Market Cap:64.07M

PE:2.12

High:0.8244

Open:0.7700

Low:0.7602

Close:0.7573

Loading ...

Overview Company News Filings

CytomX Therapeutics Announces Executive Departure and Severance

Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

Simply Wall St.

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer

Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTMX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","market":"US","secType":"STK","nameCN":"CytomX Therapeutics","latestPrice":0.7999,"timestamp":1746215878323,"preClose":0.7573,"halted":0,"volume":1358427,"delay":0,"floatShares":73975171,"shares":80099889,"eps":0.377419,"marketStatus":"Trading","change":0.0426,"latestTime":"05-02 15:58:00 EDT","open":0.77,"high":0.8244,"low":0.7602,"amount":1084806.46640142,"amplitude":0.084775,"askPrice":0.8023,"askSize":2200,"bidPrice":0.7975,"bidSize":354,"shortable":3,"etf":0,"ttmEps":0.377419,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746216000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1444276800000,"exchange":"NASDAQ","adjPreClose":0.7573,"preHourTrading":{"tag":"盘前","latestPrice":0.77,"preClose":0.7573,"latestTime":"09:14 EDT","volume":79088,"amount":58327.32565728,"timestamp":1746191694816},"postHourTrading":{"tag":"盘后","latestPrice":0.740751,"preClose":0.7573,"latestTime":"19:52 EDT","volume":38358,"amount":28763.42202,"timestamp":1746143551864},"volumeRatio":0.741856,"impliedVol":2.0844,"impliedVolPercentile":0.692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTMX\",,,,,undefined,":{"symbol":"CTMX","floatShares":73975171,"roa":"9.69%","roe":"-139.27%","lyrEps":0.377419,"volumeRatio":0.741856,"shares":80099889,"dividePrice":0,"high":0.8244,"amplitude":0.084775,"preClose":0.7573,"low":0.7602,"week52Low":0.4,"pbRate":"-140.51","psRate":"0.46","week52High":5.06,"institutionHeld":0,"latestPrice":0.7999,"committee":-0.722788,"eps":0.377419,"divideRate":0,"volume":1358427,"delay":0,"ttmEps":0.377419,"open":0.77,"prevYearClose":1.03,"prevWeekClose":0.71,"prevMonthClose":0.7443,"prevQuarterClose":0.6358,"fiveDayClose":0.71,"twentyDayClose":0.5431,"sixtyDayClose":0.9376},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTMX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508175666","title":"CytomX Therapeutics Announces Executive Departure and Severance","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175666","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175666?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:36","pubTimestamp":1738618605,"startTime":"0","endTime":"0","summary":"An announcement from CytomX Therapeutics ( ($CTMX) ) is now available. On January 30, 2025, CytomX Therapeutics announced the termination of employ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-announces-executive-departure-and-severance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cytomx-therapeutics-announces-executive-departure-and-severance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTMX"],"gpt_icon":0},{"id":"2507631655","title":"Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2507631655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507631655?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:21","pubTimestamp":1738160475,"startTime":"0","endTime":"0","summary":"Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held CytomX Therapeutics, Inc.  for five years would be nursing their metaphorical wounds since the share price dropped 89% in that time. And some of the more recent buyers are probably worried, too, with the stock falling 46% in the last year. Unfortunately the share price momentum is still quite negative, with prices down 21% in thirty days. While a drop like that is definitely a body blow, money isn't as important as health and happiness.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholders-cytomx-therapeutics-nasdaq-ctmx-142115313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4139","USJW.SI","IE00BKPKM429.USD","NVIW.SI","NDAQ","MNQmain",".IXIC","IE00B64PRP62.GBP","TSYW.SI","CTMX","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","QLD","USAW.SI","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","LU2095319765.USD","QID","SQQQ","BK4585","BK4588","TQQQ"],"gpt_icon":1},{"id":"2507543472","title":"PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2507543472","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507543472?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:22","pubTimestamp":1738077720,"startTime":"0","endTime":"0","summary":"Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan. 25.With the expiry of the deadline, Starboard has foregone an opportunity to bring changes in PFE’s board. This signals a less confrontational approach, at least for this year. Shareholders are set to convene at Pfizer’s annual meeting in April to vote on director seats for the year.The article, however, pointed out that Starboard could still try to make the changes in Pfizer’s board next year if the two parties are unable to reach an agreement.Bloomberg claims to have contacted both Pfizer and Starboard, who have either declined to comment on the above news or are yet to respond.The above article provides some respite to Pfizer’s management, which was accused last year by Starboard of making poor capital allocation, research and development (R&D) failures and problems with forecasting and budge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfe-stock-rises-reports-averting-152200714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","CTMX","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","ERAS","SGXZ57979304.SGD","BK4539","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4196","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","CSTL","IE0002270589.USD","BK4533","IE00B19Z3B42.SGD","LU0122379950.USD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","BK4139","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2505044214","title":"CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505044214","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505044214?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:19","pubTimestamp":1737649140,"startTime":"0","endTime":"0","summary":"Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 , a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction  with left ventricular ejection fraction  ≥60%.Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry’s 8.7% decline.Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated withhypertrophic cardiomyopathy . A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4531","BK4196","BK4585","IE00B19Z3581.USD","BK4139","BK4566","HCM","BK4007","IE00B7SZLL34.SGD","CYTK","BK4505","IE0002270589.USD","BK4588","CTMX","IE00B19Z3B42.SGD","CSTL","BMRN"],"gpt_icon":0},{"id":"2505489620","title":"Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2505489620","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505489620?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:13","pubTimestamp":1737641580,"startTime":"0","endTime":"0","summary":"Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept , to treat patients with pulmonary arterial hypertension , a kind of lung disease.Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee . Cibotercept is an investigational modified ActRIIB fusion protein.The phase II TROPOSstudy is evaluating three doses of cibotercept  in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-stock-plunges-81-141300812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","IE00B19Z3581.USD","BK4196","BMRN","IE00B19Z3B42.SGD","CTMX","KROS","CSTL","BK4566","IE00B7SZLL34.SGD","BK4139","IE0002270589.USD"],"gpt_icon":0},{"id":"2505230363","title":"AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505230363","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505230363?lang=en_us&edition=fundamental","pubTime":"2025-01-21 03:05","pubTimestamp":1737399900,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate ,datopotamab deruxtecan , in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway.Post the FDA’s approval, the ADC drug is approved to treat unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.This approval came just a few weeks after Daiichi secured approval for the drug for a similar indication in Japan. The approvals in the United States and Japan are based on data from the phase III TROPION-Breast01 study, which showed that treatment with Datroway significantly reduced the risk of disease progression or death by 37% compared to the investigator’s choice of chemotherapy in the above indication.Per AstraZeneca, Datroway is part of a select group of therapies that could achieve peak annual sales of at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-secures-fda-nod-adc-190500987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2456880835.USD","LU2417539215.USD","BK4080","BK4231","BK4139","LU0109394709.USD","BK4568","LU2462157665.USD","ADC","LU1829250122.USD","BK4585","CTMX","BK4196","LU0889565916.HKD","BK4539","BK4007","LU0320765992.SGD","LU2236285917.USD","ERAS","CSTL","BK4588","AZN"],"gpt_icon":0},{"id":"2505287123","title":"Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505287123","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505287123?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:18","pubTimestamp":1737382680,"startTime":"0","endTime":"0","summary":"Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras , in combination with its anti-EGFR antibody, Vectibix , for treating KRAS G12C-mutated metastatic colorectal cancer .The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.Lumakras is presently approved for treating advanced or metastatic non-small cell lung cancer . The drug was approved in the United States in May 2021 and in the EU  in January 2022.In the past year, shares of Amgen have dropped 12.2% compared with the industry’s decline of 14.1%.Lumakras’ approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS G12C–mutated mCRC.Data from the CodeBreaK 300 study also showed that treatment with Lumakras plus Vectibix demonstrated favorable ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgens-lumakras-gets-fda-nod-141800343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","IE00BFTCPJ56.SGD","BK4213","IE00B4R5TH58.HKD","LU1023059063.AUD","LU2242646821.SGD","BK4599","IE00BJT1NW94.SGD","SOC","BK4195","IE00B2B36J28.USD","LU0058720904.USD","LU2112291526.USD","BK4211","VYGR","BK4588","BK4566","LU2242652126.USD","CSTL","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","IE0002141913.USD","LU0868494617.USD","BK4534","LU0122379950.USD","BK4139","PFS","BK4585","AMGN","LU0889565916.HKD","LU1057294990.SGD","SG9999001440.SGD","LU1061106388.HKD","LU1983299246.USD","IE0009355771.USD","LU0289739699.SGD","LU1571399168.USD","CTMX","BK4581","BK4533"],"gpt_icon":0},{"id":"2504929191","title":"Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504929191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504929191?lang=en_us&edition=fundamental","pubTime":"2025-01-17 23:28","pubTimestamp":1737127680,"startTime":"0","endTime":"0","summary":"Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen , its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024.In the past year, shares of Stoke Therapeutics have rallied 94.7% against the industry’s decline of 13.6%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.6%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have decreased 49.5%.CTMX’s earnings beat estimates in two of the trailing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-stoke-therapeutics-152800824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTMX","STOK","CSTL","VYGR","BK4196","LENZ","BK4139"],"gpt_icon":0},{"id":"2504195429","title":"ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195429","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504195429?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:24","pubTimestamp":1737123840,"startTime":"0","endTime":"0","summary":"Tab-cel, the company’s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre under an exclusive commercialization and license agreement.EBV+ PTLD is a rare hematologic malignancy  with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.In the past three months, Atara shares have lost 16.8% compared with the industry’s 12.2% decline.More on the FDA’s CRL Issuance Against ATRA’s Ebvallo. Atara is eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, providing a critical cash infusion for the company. Additionally, it will be eligible for substantial double-digit tiered royalties based on net sales and further milestones tied to Ebvallo's commercial performance. However, the FDA's CRL has also delayed the milestone payment, impacting funds the company planned to allocate for sup","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atra-stock-down-fda-issues-142400167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","BK4585","BK4139","BK4566","IE0002270589.USD","BMRN","IE00B19Z3B42.SGD","BK4196","BK4588","IE00B19Z3581.USD","ATRA","IE00B7SZLL34.SGD","CSTL","BK4530","CTMX","CRL","LU0390134368.USD"],"gpt_icon":0},{"id":"2504949490","title":"MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2504949490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504949490?lang=en_us&edition=fundamental","pubTime":"2025-01-17 01:09","pubTimestamp":1737047340,"startTime":"0","endTime":"0","summary":"Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli , which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.MIRM acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.In the past year, shares of Mirum have rallied 73.3% against the industry’s decline of 16%.Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis  patients is currently under review in the United States. A decisi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirm-shares-rise-12-week-170900763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRM","BK4196","VYGR","BK4139","CSTL","CTMX"],"gpt_icon":0},{"id":"2504433569","title":"InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2504433569","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504433569?lang=en_us&edition=fundamental","pubTime":"2025-01-16 23:49","pubTimestamp":1737042540,"startTime":"0","endTime":"0","summary":"InflaRx N.V.IFRX shares gained 7.7% on Wednesday following the European Commission's  approval of marketing authorization, under exceptional circumstances, for Gohibic  to treat adult patients with acute respiratory distress syndrome  caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.The EC’s approval makes Gohibic the first and only approved treatment for SARS-CoV-2-induced ARDS in the EU. We remind the investors that in November 2024, the advisory committee to the European Medicines Agency had adopted a positive opinion recommending approval of the drug for the above indication, under exceptional circumstances. Gohibic is a first-in-class anti-C5a monoclonal antibody.More on the EC Nod for IFRX’s COVID-19-Induced ARDS Drug. The EU approval ofInflaRx’s Gohibic for the ADRS indication is ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-stock-rises-8-conditional-154900009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4452.SGD","BK4551","CTMX","LU2552382215.SGD","IE000M9KFDE8.USD","LU0320765646.SGD","IFRX","LU2552382132.HKD","CSTL","LU1066051498.USD","BK4139","BK4581","LU0689626769.HKD","LU1868836591.USD","LU1929549753.HKD","BMRN","LU0124676726.USD","BK4504","LU1430594728.SGD","BK4196","LU1280957306.USD","BK4568","ARDS","LU0868494617.USD","PG","BK4548","LU0640476718.USD","BK4018","SG9999001440.SGD","EC","BNTX","LU1868837300.USD","SG9999014559.SGD","IE00B7SZLL34.SGD","LU2242652126.USD","SG9999015358.SGD","SG9999014575.USD","LU1868837136.USD","IE00BWXC8680.SGD","LU0098860793.USD","SG9999002232.USD","IE00BBT3K403.USD","LU0094547139.USD","SG9999002224.SGD","BK4201","BK4533","LU0061475181.USD","LU2242646821.SGD","IE00BLSP4239.USD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2503273621","title":"TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2503273621","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503273621?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:10","pubTimestamp":1736950200,"startTime":"0","endTime":"0","summary":"TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi , which exceeded the company’s initial expectations.TGTX also provided its guidance for 2025 and outlined some expected milestones related to Briumvi label expansion studies and other pipeline candidates for 2025.Briumvi is approved for the treatment of certain adult patients with relapsing forms of multiple sclerosis .In the past year, shares of TG Therapeutics have rallied 96.2% against the industry’s decline of 14.8%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 33%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.5%.CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tgtx-announces-2024-preliminary-results-141000241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089283258.USD","BK4504","LU1668664300.SGD","LU1162221912.USD","LU0106261372.USD","TGTX","VYGR","LU1363072403.SGD","BK4581","BK4139","LU1989772840.SGD","LU2271345857.HKD","BK4585","BK4588","LU1732799900.SGD","LU0267386448.USD","LU2111349929.HKD","LU1720051108.HKD","LU1074936037.SGD","LU2347655156.SGD","IE00BZ1G4Q59.USD","BK4534","LU0971096721.USD","LU0006306889.USD","LU1720051017.SGD","LU0158827948.USD","LU1989772923.USD","LU2023251221.USD","LU2089284900.SGD","IE00BKVL7J92.USD","CSTL","CTMX","LU0106831901.USD","LU0314104364.USD","BK4196","BK4127","BK4516","LU0912757837.SGD","LU0225283273.USD","LU0320765646.SGD","LU0795875169.SGD","LU1548497426.USD","LU2357305700.SGD","LU2028103732.USD","LU0158827781.USD","LU0098860793.USD","LU0795875086.SGD","LU1732800096.USD"],"gpt_icon":0},{"id":"2503056435","title":"Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503056435","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503056435?lang=en_us&edition=fundamental","pubTime":"2025-01-14 23:14","pubTimestamp":1736867640,"startTime":"0","endTime":"0","summary":"Shares of Blueprint MedicinesBPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise.Blueprint’s commercial portfolio only comprises its lead drug Ayvakit , an inhibitor of KIT and PDGFRA proteins,which was initially approved in the United States and the EU to treat gastrointestinal stromal tumors in 2020. Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis .The company anticipates reporting its fourth-quarter and full-year 2024 results in February 2025. In October 2024, Blueprint projected Ayvakit product revenues in the range of $475-$480 million for the year, marking growth of more than 130% compared with 2023. The growth trajectory of Ayvakit sales is expected to continue rising in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blueprint-stock-soars-18-encouraging-151400664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","SM","BK4213","CTMX","BPMC","HALO","BK4505","CSTL","BK4139","BK4196"],"gpt_icon":0},{"id":"2503547052","title":"SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503547052","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503547052?lang=en_us&edition=fundamental","pubTime":"2025-01-14 17:16","pubTimestamp":1736846160,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous  formulation of its blood cancer drug, Sarclisa  for the treatment of relapsed or refractory multiple myeloma  has met the co-primary endpoints.Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ BMY Pomalyst  and dexamethasone  when administered through an on-body delivery system  demonstrated non-inferiority in objective response rate  and observed concentration before dosing  as compared to currently approved intravenous  formulation of Sarclisa administered at a weight-based dose in combination with Pd in the given patient population.ORR and C trough were the two co-primary endpoints of the IRAKLIA study. It is also the first phase III study to evaluate the SC administration of a cancer drug via an OBDS. Per the company, OBDS is a substitute delivery method planned to improve the patient experience and currently available SC administrati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snys-subcutaneous-sarclisa-proves-non-091600551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU1032466523.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","PBYI","BK4585","LU2360032135.SGD","IE0009355771.USD","LU2125154778.USD","LU1093756168.USD","LU0096364046.USD","LU0882574055.USD","LU1989771016.USD","LU1670710661.SGD","CTMX","LU0985481810.HKD","LU1323610961.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","BK4139","LU1670710588.SGD","CHMP","LU1868837300.USD","BK4532","LU1291159041.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU1670711040.USD","BK4534","LU2242652126.USD","LU0114720955.EUR","BK4087","LU1868836757.USD","LU1261432733.SGD","BMY","LU2125154935.USD","BK4581","LU0225284248.USD","LU1670711123.USD","LU1430594728.SGD","LU0306807586.USD","LU0321505868.SGD","BK4007","LU0321505439.SGD","LU0868494617.USD","SNY","IE0002141913.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2503353959","title":"PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2503353959","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503353959?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:43","pubTimestamp":1736786580,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.Pacira did not recognize any other revenues, comprising sales of bupivacaine liposome injectable suspension and royalties, in the fourth quarter of 2024. In the year-ago period, the company recognized $2.6 million in other revenues.Pacira has outlined its ambitious \"5x30\" strategy, a growth-oriented plan designed to drive innovation and value creation by 2030. Central to this vision is the goal of treating more than three million patients annually while achieving a double-digit compounded annual growth rate in product revenues. The c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-rises-11-upbeat-164300518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","CSTL","CTMX","HALO"],"gpt_icon":0},{"id":"2503534916","title":"ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz","url":"https://stock-news.laohu8.com/highlight/detail?id=2503534916","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503534916?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:40","pubTimestamp":1736786400,"startTime":"0","endTime":"0","summary":"Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire. The litigation is currently pending in the U.S. District Court in New Jersey.Caplyta is approved in the United States for the treatment of schizophrenia in adults. Later, its indication was expanded to treat bipolar depression in adults. Intra-Cellular’s Caplyta is currently the only approved treatment, both as monotherapy and as adjunctive therapy with lithium or valproate, for depressive episodes associated with bipolar depression in adults.In 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itci-stock-rises-15-settling-164000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0053671581.USD","LU0012050646.USD","CSTL","LU0320765992.SGD","BK4196","LU0109394709.USD","CTMX","ITCI","BK4007","LU0106261612.USD","LU0889565916.HKD","SDZNY"],"gpt_icon":0},{"id":"2503391055","title":"Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503391055","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503391055?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:31","pubTimestamp":1736785860,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold , which is approved for treating Fabry disease and Pombiliti + Opfolda.The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.In the past year, shares of Amicus have plunged 31.6% compared with the industry’s decline of 16%.For full-year 2025, management expects total revenues to grow in the range of 17%-24% on a constant exchange rate .Revenues from Galafold are expected to grow in the range of 10%-15% at CER in 2025.Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.Amicus expects to achieve positive GAAP net income in the second half of 2025. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amicus-posts-preliminary-2024-results-163100240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","BK4559","FOLD","LU2065169927.USD","BK4584","BK4588","TEVA","BK4596","BK4557","LU2065171311.SGD","LU2065171402.SGD","CSTL","CTMX","LU2065170008.USD","BK4139","BK4196","BK4566"],"gpt_icon":0},{"id":"2502520890","title":"SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2502520890","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502520890?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:16","pubTimestamp":1736522160,"startTime":"0","endTime":"0","summary":"Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes  study of its experimental cell therapy, UP421.Notably, in the investigator-sponsored, first-in-human study, UP421 was transplanted into a patient with T1D without the use of any immunosuppression. UP421, an allogeneic primary islet cell therapy, is being developed in partnership with Uppsala University Hospital, utilizing Sana’s proprietary hypoimmune  technology.The study results were evaluated four weeks after intramuscular cell transplantation, which confirmed the survival and functionality of pancreatic beta cells in the first treated T1D patient. The results were supported by the presence of circulating C-peptide, a biomarker indicating insulin production by the transplanted beta cells.C-peptide levels further increased during a mixed meal tolerance test, demonstrating insulin secretion in response to a meal. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sana-stock-surges-152-week-151600351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","CTMX","CSTL","BK4139","SANA","HALO","LU0053671581.USD"],"gpt_icon":1},{"id":"2502681892","title":"NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2502681892","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502681892?lang=en_us&edition=fundamental","pubTime":"2025-01-10 22:56","pubTimestamp":1736520960,"startTime":"0","endTime":"0","summary":"Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic reorganization to prioritize its portfolio of late-stage pipeline candidates and key anticipated milestones for 2025.As part of this portfolio reorganization, NTLA is planning to prioritize the development of its investigational in vivo genome-editing candidate, Nexiguran ziclumeran , which is being studied for two indications, ATTR amyloidosis with polyneuropathy  and ATTR amyloidosis with cardiomyopathy .Intellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema .In the past year, shares of Intellia have plunged 57.3% compared with the industry’s decline of 14.3%.Owing to the latest portfolio reorganization, Intellia has decided to stop the development of its in vivo gene insertion candidate, NTLA-3001, for the treatment of alpha-1 antitrypsin deficiency  associated lung disease.Also, with the strategic reorganizat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ntla-announces-strategic-reorganization-job-145600340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2362540622.SGD","LU0882574055.USD","PBYI","LU2237438978.USD","LU0205194284.USD","BK4139","LU0205193047.USD","BK4585","HAE","LU0053666078.USD","LU0109394709.USD","BK4556","LU0320765992.SGD","BK4588","IE00B64QTZ34.USD","IE00BLDYK493.USD","REGN","LU1861558580.USD","LU0114720955.EUR","BK4535","LU2468319806.SGD","LU0289739699.SGD","LU2023250504.SGD","BK4198","CTMX","LU0823416689.USD","LU2362541513.USD","LU1169590202.USD","LU0012050646.USD","LU1974910355.USD","LU1861559042.SGD","LU2089984988.USD","LU0058720904.USD","NTLA","LU0889565916.HKD","LU0106261612.USD","LU1917777945.USD","LU2362541273.HKD","LU2106854487.HKD","LU1169589451.USD"],"gpt_icon":0},{"id":"2502468898","title":"FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2502468898","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502468898?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:24","pubTimestamp":1736515440,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor  blocker, in generalized myasthenia gravis  indication.The filing has been granted priority review by the FDA, bringing down the review period by four months. We expect a final decision in the third quarter of 2025.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care achieved sustained disease controlover 24 weeks compared with those who received placebo plus SOC. A similar regulatory filing for the drug is under review by the EMA, also supported by data from this study.Per J&J, the above results make Vivacity-MG3 the first and only study to achieve sustained disease control in gMG patients wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-j-js-filing-132400420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1162221912.USD","LU1066051225.USD","LU0466842654.USD","LU0114720955.EUR","LU1280957306.USD","SG9999002224.SGD","LU0345770993.USD","IE00B1BXHZ80.USD","LU0058720904.USD","JNJ","IE00B4R5TH58.HKD","IE0002270589.USD","LU1674673691.USD","LU0109394709.USD","LU1732800096.USD","BK4550","LU0234570918.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU0345770308.USD","LU1057294990.SGD","LU0320765992.SGD","CSTL","IE00B2B36J28.USD","LU0792757196.USD","ARGX","IE0034235303.USD","LU1032955483.USD","SG9999001440.SGD","CTMX","LU0889565916.HKD","LU1244550577.SGD","BK4139","LU1935042991.SGD","LU0912757837.SGD","BK4213","LU0098860793.USD","LU0320765646.SGD","BK4533","LU0122379950.USD","LU1066051498.USD","LU1221951046.USD","BK4505","LU1032466523.USD","LU1894683264.USD","SOC","IE00BVYPNV92.GBP","LU1261432733.SGD","IE0009355771.USD","LU0345769128.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-06","symbol":"CTMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741237200000,"reportTimeType":"post","actualEps":0.22},{"market":"US","date":"2024-11-07","symbol":"CTMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-08","symbol":"CTMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2024-05-08","symbol":"CTMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":0.17},{"market":"US","date":"2024-03-11","symbol":"CTMX","fiscalQuarterEnding":"2023/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710129600000,"reportTimeType":"post","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1716868800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTMX","date":"2025-05-01","current":1.870732,"percent":0.843699,"low":-610.657204,"twenty":-6.68943,"median":-2.165629,"eighty":-0.901293,"high":17.165432,"avg":-11.872763,"sd":52.524727,"marketCap":59618347},"quantilePoints":[{"date":"2020-05-08","current":-8.614874,"twenty":-20.96649,"median":-14.485274,"eighty":-5.651753,"marketCap":653946439},{"date":"2020-05-15","current":-5.450843,"twenty":-20.918622,"median":-14.471485,"eighty":-5.641954,"marketCap":413768077},{"date":"2020-05-22","current":-5.614187,"twenty":-20.869441,"median":-14.412035,"eighty":-5.625223,"marketCap":426167342},{"date":"2020-05-29","current":-5.360097,"twenty":-20.855205,"median":-14.387729,"eighty":-5.607113,"marketCap":406879596},{"date":"2020-06-05","current":-4.876115,"twenty":-20.837411,"median":-14.371018,"eighty":-5.579894,"marketCap":370141032},{"date":"2020-06-12","current":-4.815618,"twenty":-20.712849,"median":-14.355987,"eighty":-5.538565,"marketCap":365548711},{"date":"2020-06-19","current":-4.991061,"twenty":-20.67726,"median":-14.320237,"eighty":-5.498237,"marketCap":378866441},{"date":"2020-06-26","current":-4.960812,"twenty":-20.659465,"median":-14.307541,"eighty":-5.450843,"marketCap":376570281},{"date":"2020-07-02","current":-5.087857,"twenty":-20.576155,"median":-14.261373,"eighty":-5.410082,"marketCap":386214154},{"date":"2020-07-10","current":-5.15743,"twenty":-20.54514,"median":-14.219636,"eighty":-5.323504,"marketCap":391495322},{"date":"2020-07-17","current":-5.217927,"twenty":-20.527127,"median":-14.149251,"eighty":-5.258418,"marketCap":396087643},{"date":"2020-07-24","current":-4.694622,"twenty":-20.508161,"median":-14.129808,"eighty":-5.184654,"marketCap":356364070},{"date":"2020-07-31","current":-4.240889,"twenty":-20.453444,"median":-14.109343,"eighty":-5.169529,"marketCap":321921667},{"date":"2020-08-07","current":-5.620336,"twenty":-20.373286,"median":-14.106574,"eighty":-5.154405,"marketCap":351984762},{"date":"2020-08-14","current":-5.063465,"twenty":-20.352356,"median":-14.089783,"eighty":-5.154405,"marketCap":317109631},{"date":"2020-08-21","current":-5.126159,"twenty":-20.331137,"median":-14.019604,"eighty":-5.154405,"marketCap":321035970},{"date":"2020-08-28","current":-5.266299,"twenty":-20.312283,"median":-14.008481,"eighty":-5.154405,"marketCap":329812493},{"date":"2020-09-04","current":-4.838504,"twenty":-20.247683,"median":-13.96477,"eighty":-5.153195,"marketCap":303021002},{"date":"2020-09-11","current":-4.963892,"twenty":-20.22172,"median":-13.958967,"eighty":-5.109636,"marketCap":310873680},{"date":"2020-09-18","current":-5.458069,"twenty":-20.170596,"median":-13.951802,"eighty":-5.125358,"marketCap":341822472},{"date":"2020-09-25","current":-5.015523,"twenty":-20.11461,"median":-13.913989,"eighty":-5.067288,"marketCap":314107136},{"date":"2020-10-02","current":-4.772122,"twenty":-20.08008,"median":-13.899365,"eighty":-5.057355,"marketCap":298863702},{"date":"2020-10-09","current":-5.026586,"twenty":-20.064176,"median":-13.876559,"eighty":-5.053194,"marketCap":314800020},{"date":"2020-10-16","current":-5.059777,"twenty":-20.057081,"median":-13.857118,"eighty":-5.052064,"marketCap":316878670},{"date":"2020-10-23","current":-4.98602,"twenty":-20.043774,"median":-13.828188,"eighty":-5.029108,"marketCap":312259447},{"date":"2020-10-30","current":-4.882759,"twenty":-20.036656,"median":-13.801088,"eighty":-5.021444,"marketCap":305792536},{"date":"2020-11-06","current":-6.049502,"twenty":-20.01928,"median":-13.780006,"eighty":-5.018995,"marketCap":324495302},{"date":"2020-11-13","current":-6.376968,"twenty":-20.003719,"median":-13.762466,"eighty":-5.021444,"marketCap":342060574},{"date":"2020-11-20","current":-6.308028,"twenty":-19.990391,"median":-13.711175,"eighty":-5.022352,"marketCap":338362622},{"date":"2020-11-27","current":-6.394203,"twenty":-19.977759,"median":-13.596608,"eighty":-5.024373,"marketCap":342985062},{"date":"2020-12-04","current":-6.376968,"twenty":-19.969125,"median":-13.573758,"eighty":-5.026896,"marketCap":342060574},{"date":"2020-12-11","current":-6.532084,"twenty":-19.953786,"median":-13.48235,"eighty":-5.028526,"marketCap":350380967},{"date":"2020-12-18","current":-6.738904,"twenty":-19.927699,"median":-13.396874,"eighty":-5.032258,"marketCap":361474823},{"date":"2020-12-24","current":-6.394203,"twenty":-19.920158,"median":-13.309968,"eighty":-5.03608,"marketCap":342985062},{"date":"2020-12-31","current":-5.644479,"twenty":-19.913392,"median":-13.266804,"eighty":-5.039459,"marketCap":302769833},{"date":"2021-01-08","current":-6.376968,"twenty":-19.876131,"median":-13.133036,"eighty":-5.051559,"marketCap":342060574},{"date":"2021-01-15","current":-6.833697,"twenty":-19.875411,"median":-13.071715,"eighty":-5.052401,"marketCap":366559507},{"date":"2021-01-22","current":-7.50172,"twenty":-19.86922,"median":-13.049885,"eighty":-5.052401,"marketCap":402392271},{"date":"2021-01-29","current":-7.795021,"twenty":-19.846267,"median":-13.019446,"eighty":-5.053459,"marketCap":418124901},{"date":"2021-02-05","current":-9.390938,"twenty":-19.831701,"median":-12.942812,"eighty":-5.058566,"marketCap":503729902},{"date":"2021-02-12","current":-10.512244,"twenty":-19.824377,"median":-12.897211,"eighty":-5.059777,"marketCap":563876757},{"date":"2021-02-19","current":-10.418802,"twenty":-19.821989,"median":-12.77593,"eighty":-5.06199,"marketCap":558864519},{"date":"2021-02-26","current":-15.976239,"twenty":-19.809797,"median":-12.810718,"eighty":-5.063581,"marketCap":525378614},{"date":"2021-03-05","current":-15.833776,"twenty":-19.799678,"median":-12.921607,"eighty":-5.067288,"marketCap":520693709},{"date":"2021-03-12","current":-17.299112,"twenty":-19.76851,"median":-12.921607,"eighty":-5.067288,"marketCap":568881302},{"date":"2021-03-19","current":-16.831018,"twenty":-19.712796,"median":-12.921607,"eighty":-5.067288,"marketCap":553488043},{"date":"2021-03-26","current":-15.508145,"twenty":-19.620977,"median":-12.922693,"eighty":-5.068498,"marketCap":509985355},{"date":"2021-04-01","current":-16.016943,"twenty":-19.574255,"median":-12.922693,"eighty":-5.068498,"marketCap":526717158},{"date":"2021-04-09","current":-15.711664,"twenty":-19.474349,"median":-12.921607,"eighty":-5.067288,"marketCap":516678076},{"date":"2021-04-16","current":-15.284274,"twenty":-19.423718,"median":-12.921607,"eighty":-5.067288,"marketCap":502623362},{"date":"2021-04-23","current":-18.642337,"twenty":-19.348547,"median":-12.921607,"eighty":-5.067288,"marketCap":613053261},{"date":"2021-04-30","current":-18.502039,"twenty":-19.318728,"median":-12.921607,"eighty":-5.067288,"marketCap":608439564},{"date":"2021-05-07","current":-9.165707,"twenty":-19.246205,"median":-12.845506,"eighty":-5.067288,"marketCap":555845161},{"date":"2021-05-14","current":-8.747623,"twenty":-19.199134,"median":-12.654171,"eighty":-5.067288,"marketCap":530490820},{"date":"2021-05-21","current":-9.015626,"twenty":-19.199134,"median":-12.54111,"eighty":-5.067288,"marketCap":546743603},{"date":"2021-05-28","current":-7.67561,"twenty":-19.19054,"median":-12.410655,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-04","current":-7.257525,"twenty":-19.109305,"median":-12.334551,"eighty":-5.067288,"marketCap":440125350},{"date":"2021-06-11","current":-7.67561,"twenty":-19.109305,"median":-12.217538,"eighty":-5.067288,"marketCap":465479690},{"date":"2021-06-18","current":-7.69705,"twenty":-19.109305,"median":-12.148707,"eighty":-5.067288,"marketCap":466779913},{"date":"2021-06-25","current":-6.914481,"twenty":-19.109305,"median":-12.059624,"eighty":-5.067288,"marketCap":419321788},{"date":"2021-07-02","current":-6.689358,"twenty":-19.101131,"median":-12.035228,"eighty":-5.067288,"marketCap":405669451},{"date":"2021-07-09","current":-6.507116,"twenty":-19.096054,"median":-12.010832,"eighty":-5.067288,"marketCap":394617559},{"date":"2021-07-16","current":-6.206953,"twenty":-19.021876,"median":-11.953909,"eighty":-5.067288,"marketCap":376414442},{"date":"2021-07-23","current":-5.94967,"twenty":-18.950858,"median":-11.888854,"eighty":-5.067288,"marketCap":360811771},{"date":"2021-07-30","current":-5.799588,"twenty":-18.890929,"median":-11.811434,"eighty":-5.067288,"marketCap":351710213},{"date":"2021-08-06","current":-5.327596,"twenty":-18.810436,"median":-11.750611,"eighty":-5.067288,"marketCap":342074265},{"date":"2021-08-13","current":-4.921684,"twenty":-18.643395,"median":-11.628633,"eighty":-5.057355,"marketCap":316011464},{"date":"2021-08-20","current":-4.728875,"twenty":-18.537367,"median":-11.542992,"eighty":-5.037769,"marketCap":303631633},{"date":"2021-08-27","current":-5.266709,"twenty":-18.470044,"median":-11.449731,"eighty":-5.033251,"marketCap":338164845},{"date":"2021-09-03","current":-5.21597,"twenty":-18.282192,"median":-11.400939,"eighty":-5.033251,"marketCap":334906995},{"date":"2021-09-10","current":-5.195674,"twenty":-18.214367,"median":-11.287092,"eighty":-5.033251,"marketCap":333603855},{"date":"2021-09-17","current":-5.3073,"twenty":-18.011705,"median":-11.171304,"eighty":-5.033251,"marketCap":340771125},{"date":"2021-09-24","current":-5.337744,"twenty":-17.880773,"median":-11.075663,"eighty":-5.033251,"marketCap":342725835},{"date":"2021-10-01","current":-5.185526,"twenty":-17.786094,"median":-11.006109,"eighty":-5.029108,"marketCap":332952285},{"date":"2021-10-08","current":-4.901388,"twenty":-17.593674,"median":-10.888629,"eighty":-5.022352,"marketCap":314708324},{"date":"2021-10-15","current":-5.21597,"twenty":-17.347957,"median":-10.734122,"eighty":-5.022352,"marketCap":334906995},{"date":"2021-10-22","current":-5.418926,"twenty":-17.286901,"median":-10.255278,"eighty":-5.022352,"marketCap":347938396},{"date":"2021-10-29","current":-6.017646,"twenty":-17.190067,"median":-10.091754,"eighty":-5.022352,"marketCap":386381027},{"date":"2021-11-05","current":-5.974365,"twenty":-17.127695,"median":-9.91655,"eighty":-5.022352,"marketCap":430644165},{"date":"2021-11-12","current":-6.354552,"twenty":-17.127695,"median":-9.702195,"eighty":-5.022352,"marketCap":458048794},{"date":"2021-11-19","current":-6.644218,"twenty":-17.127695,"median":-9.581303,"eighty":-5.022352,"marketCap":478928511},{"date":"2021-11-26","current":-6.110146,"twenty":-17.127695,"median":-9.533121,"eighty":-5.022352,"marketCap":440431533},{"date":"2021-12-03","current":-5.983417,"twenty":-17.127695,"median":-9.402102,"eighty":-5.022352,"marketCap":431296656},{"date":"2021-12-10","current":-5.693751,"twenty":-17.127695,"median":-9.370943,"eighty":-5.022352,"marketCap":410416939},{"date":"2021-12-17","current":-5.784271,"twenty":-17.127695,"median":-9.309923,"eighty":-5.022352,"marketCap":416941851},{"date":"2021-12-23","current":-3.819973,"twenty":-17.127695,"median":-9.214034,"eighty":-5.015418,"marketCap":275351269},{"date":"2021-12-31","current":-3.919545,"twenty":-17.127695,"median":-9.097316,"eighty":-4.989045,"marketCap":282528672},{"date":"2022-01-07","current":-3.521254,"twenty":-17.119715,"median":-9.010266,"eighty":-4.966268,"marketCap":253819061},{"date":"2022-01-14","current":-3.575567,"twenty":-17.119715,"median":-8.988637,"eighty":-4.961982,"marketCap":257734008},{"date":"2022-01-21","current":-3.883337,"twenty":-17.119715,"median":-8.85398,"eighty":-4.955638,"marketCap":279918707},{"date":"2022-01-28","current":-3.98291,"twenty":-17.119715,"median":-8.805781,"eighty":-4.940695,"marketCap":287096110},{"date":"2022-02-04","current":-3.856181,"twenty":-17.119715,"median":-8.758021,"eighty":-4.932273,"marketCap":277961234},{"date":"2022-02-11","current":-3.946702,"twenty":-17.119715,"median":-8.737148,"eighty":-4.904186,"marketCap":284486145},{"date":"2022-02-18","current":-3.711348,"twenty":-17.119715,"median":-8.689552,"eighty":-4.87848,"marketCap":267521375},{"date":"2022-02-25","current":-3.647983,"twenty":-17.119715,"median":-8.61807,"eighty":-4.874319,"marketCap":262953937},{"date":"2022-03-04","current":-2.093787,"twenty":-17.061962,"median":-8.407346,"eighty":-4.837766,"marketCap":242607132},{"date":"2022-03-11","current":-2.009133,"twenty":-17.009918,"median":-7.958591,"eighty":-4.791418,"marketCap":232798218},{"date":"2022-03-18","current":-1.811606,"twenty":-16.798456,"median":-7.750651,"eighty":-4.667881,"marketCap":209910753},{"date":"2022-03-25","current":-1.518137,"twenty":-16.708907,"median":-7.65953,"eighty":-4.531833,"marketCap":175906519},{"date":"2022-04-01","current":-1.58586,"twenty":-16.607213,"median":-7.518984,"eighty":-4.457209,"marketCap":183753649},{"date":"2022-04-08","current":-1.50685,"twenty":-16.57374,"median":-7.379808,"eighty":-4.397775,"marketCap":174598663},{"date":"2022-04-14","current":-1.303679,"twenty":-16.518509,"median":-7.230724,"eighty":-4.340581,"marketCap":151057270},{"date":"2022-04-22","current":-1.123083,"twenty":-16.311892,"median":-6.946642,"eighty":-4.261865,"marketCap":130131588},{"date":"2022-04-29","current":-0.965144,"twenty":-16.164988,"median":-6.796842,"eighty":-4.239985,"marketCap":111831187},{"date":"2022-05-06","current":-1.152331,"twenty":-16.037314,"median":-6.714191,"eighty":-4.169443,"marketCap":105945335},{"date":"2022-05-13","current":-1.251915,"twenty":-16.037314,"median":-6.648271,"eighty":-4.143215,"marketCap":115101104},{"date":"2022-05-20","current":-1.152331,"twenty":-16.037314,"median":-6.604751,"eighty":-4.08252,"marketCap":105945335},{"date":"2022-05-27","current":-1.152331,"twenty":-16.037314,"median":-6.566259,"eighty":-4.057616,"marketCap":105945335},{"date":"2022-06-03","current":-1.266142,"twenty":-16.037314,"median":-6.522189,"eighty":-4.032826,"marketCap":116409071},{"date":"2022-06-10","current":-1.323047,"twenty":-16.037314,"median":-6.480379,"eighty":-3.97927,"marketCap":121640940},{"date":"2022-06-17","current":-1.138105,"twenty":-16.037314,"median":-6.433323,"eighty":-3.95309,"marketCap":104637368},{"date":"2022-06-24","current":-1.3515,"twenty":-16.046011,"median":-6.408864,"eighty":-3.934785,"marketCap":124256874},{"date":"2022-07-01","current":-1.308821,"twenty":-16.046011,"median":-6.389195,"eighty":-3.9179,"marketCap":120332973},{"date":"2022-07-08","current":-0.92471,"twenty":-16.046011,"median":-6.376968,"eighty":-3.872475,"marketCap":85017861},{"date":"2022-07-15","current":-1.066973,"twenty":-16.046011,"median":-6.346314,"eighty":-3.809467,"marketCap":98097532},{"date":"2022-07-22","current":-1.031408,"twenty":-16.046011,"median":-6.316646,"eighty":-3.762177,"marketCap":94827614},{"date":"2022-07-29","current":-1.017181,"twenty":-16.046011,"median":-6.308028,"eighty":-3.738504,"marketCap":93519647},{"date":"2022-08-05","current":-1.130019,"twenty":-16.046011,"median":-6.26494,"eighty":-3.711348,"marketCap":109477401},{"date":"2022-08-12","current":-1.136827,"twenty":-16.046011,"median":-6.196,"eighty":-3.671605,"marketCap":110136904},{"date":"2022-08-19","current":-1.130019,"twenty":-16.046011,"median":-6.156937,"eighty":-3.629765,"marketCap":109477401},{"date":"2022-08-26","current":-1.041524,"twenty":-16.046011,"median":-6.121192,"eighty":-3.611561,"marketCap":100903870},{"date":"2022-09-02","current":-0.993872,"twenty":-16.046011,"median":-6.09259,"eighty":-3.569146,"marketCap":96287353},{"date":"2022-09-09","current":-1.089175,"twenty":-16.046011,"median":-6.049502,"eighty":-3.532316,"marketCap":105520387},{"date":"2022-09-16","current":-1.075561,"twenty":-16.046011,"median":-6.027794,"eighty":-3.511462,"marketCap":104201382},{"date":"2022-09-23","current":-0.97345,"twenty":-16.046011,"median":-5.997351,"eighty":-3.486665,"marketCap":94308846},{"date":"2022-09-30","current":-0.987065,"twenty":-16.046011,"median":-5.96096,"eighty":-3.449721,"marketCap":95627850},{"date":"2022-10-07","current":-0.953028,"twenty":-16.046011,"median":-5.928297,"eighty":-3.414806,"marketCap":92330338},{"date":"2022-10-14","current":-0.966643,"twenty":-16.046011,"median":-5.890191,"eighty":-3.396433,"marketCap":93649343},{"date":"2022-10-21","current":-0.905377,"twenty":-16.046011,"median":-5.862972,"eighty":-3.379973,"marketCap":87713821},{"date":"2022-10-28","current":-0.918992,"twenty":-16.046011,"median":-5.831748,"eighty":-3.331334,"marketCap":89032826},{"date":"2022-11-04","current":-0.850918,"twenty":-16.046011,"median":-5.784271,"eighty":-3.323074,"marketCap":82437802},{"date":"2022-11-11","current":-0.873514,"twenty":-16.046011,"median":-5.732321,"eighty":-3.273141,"marketCap":85248833},{"date":"2022-11-18","current":-1.178228,"twenty":-16.046011,"median":-5.677883,"eighty":-3.251622,"marketCap":114986798},{"date":"2022-11-25","current":-1.225628,"twenty":-16.046011,"median":-5.650664,"eighty":-3.224416,"marketCap":119612704},{"date":"2022-12-02","current":-1.157914,"twenty":-16.046011,"median":-5.620336,"eighty":-3.195939,"marketCap":113004267},{"date":"2022-12-09","current":-1.049571,"twenty":-16.046011,"median":-5.607113,"eighty":-3.110828,"marketCap":102430768},{"date":"2022-12-16","current":-1.063114,"twenty":-16.046011,"median":-5.569007,"eighty":-2.986764,"marketCap":103752456},{"date":"2022-12-23","current":-1.049571,"twenty":-16.046011,"median":-5.5407,"eighty":-2.919362,"marketCap":102430768},{"date":"2022-12-30","current":-1.083428,"twenty":-16.046011,"median":-5.520013,"eighty":-2.905032,"marketCap":105734987},{"date":"2023-01-06","current":-1.706399,"twenty":-16.021613,"median":-5.479813,"eighty":-2.876488,"marketCap":166532604},{"date":"2023-01-13","current":-1.936628,"twenty":-15.815007,"median":-5.458069,"eighty":-2.826882,"marketCap":189001289},{"date":"2023-01-20","current":-1.706399,"twenty":-15.672234,"median":-5.418926,"eighty":-2.80972,"marketCap":166532604},{"date":"2023-01-27","current":-1.875685,"twenty":-15.467441,"median":-5.400249,"eighty":-2.756449,"marketCap":183053696},{"date":"2023-02-03","current":-1.794428,"twenty":-15.286312,"median":-5.341948,"eighty":-2.654972,"marketCap":175123572},{"date":"2023-02-10","current":-1.719942,"twenty":-14.767548,"median":-5.325305,"eighty":-2.465003,"marketCap":167854292},{"date":"2023-02-17","current":-1.598056,"twenty":-14.638832,"median":-5.295802,"eighty":-2.294544,"marketCap":155959106},{"date":"2023-02-24","current":-1.442313,"twenty":-14.517074,"median":-5.28105,"eighty":-2.219541,"marketCap":140759701},{"date":"2023-03-03","current":-1.449085,"twenty":-14.054392,"median":-5.266709,"eighty":-2.138936,"marketCap":141420545},{"date":"2023-03-10","current":-1.259485,"twenty":-13.803918,"median":-5.257251,"eighty":-2.004618,"marketCap":122916922},{"date":"2023-03-17","current":-1.259485,"twenty":-13.049016,"median":-5.222044,"eighty":-1.906833,"marketCap":122916922},{"date":"2023-03-24","current":-1.151142,"twenty":-12.765494,"median":-5.214668,"eighty":-1.859433,"marketCap":112343423},{"date":"2023-03-31","current":-1.006921,"twenty":-12.62808,"median":-5.195674,"eighty":-1.814742,"marketCap":100004349},{"date":"2023-04-06","current":-0.993584,"twenty":-12.403697,"median":-5.18509,"eighty":-1.790365,"marketCap":98679788},{"date":"2023-04-14","current":-1.153624,"twenty":-12.106258,"median":-5.17779,"eighty":-1.734306,"marketCap":114574519},{"date":"2023-04-21","current":-1.086941,"twenty":-11.986239,"median":-5.165231,"eighty":-1.693089,"marketCap":107951714},{"date":"2023-04-28","current":-1.062043,"twenty":-11.596613,"median":-5.154405,"eighty":-1.669474,"marketCap":105478911},{"date":"2023-05-05","current":-1.115479,"twenty":-11.092,"median":-5.126159,"eighty":-1.604589,"marketCap":110786026},{"date":"2023-05-12","current":-1.662065,"twenty":-10.241261,"median":-5.114492,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-18","current":-1.662065,"twenty":-10.005621,"median":-5.08928,"eighty":-1.592633,"marketCap":117419920},{"date":"2023-05-26","current":-1.605724,"twenty":-9.707425,"median":-5.066683,"eighty":-1.590375,"marketCap":113439583},{"date":"2023-06-02","current":-1.577553,"twenty":-9.509003,"median":-5.05675,"eighty":-1.577553,"marketCap":111449415},{"date":"2023-06-07","current":-1.586944,"twenty":-9.43545,"median":-5.053605,"eighty":-1.577553,"marketCap":112112805},{"date":"2023-06-16","current":-1.464871,"twenty":-9.370943,"median":-5.035235,"eighty":-1.563286,"marketCap":103488743},{"date":"2023-06-23","current":-1.42731,"twenty":-9.282028,"median":-5.023162,"eighty":-1.535759,"marketCap":100835185},{"date":"2023-06-30","current":-1.324018,"twenty":-9.164912,"median":-5.015391,"eighty":-1.507486,"marketCap":93537902},{"date":"2023-07-07","current":-1.699626,"twenty":-9.072816,"median":-4.992228,"eighty":-1.507486,"marketCap":120073477},{"date":"2023-07-14","current":-1.699626,"twenty":-8.996105,"median":-4.978644,"eighty":-1.50685,"marketCap":120073477},{"date":"2023-07-21","current":-1.680846,"twenty":-8.922199,"median":-4.962275,"eighty":-1.50685,"marketCap":118746699},{"date":"2023-07-28","current":-1.605724,"twenty":-8.822663,"median":-4.956516,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-04","current":-1.577553,"twenty":-8.779783,"median":-4.941765,"eighty":-1.50685,"marketCap":111449415},{"date":"2023-08-11","current":-2.38569,"twenty":-8.747969,"median":-4.933588,"eighty":-1.50685,"marketCap":113439583},{"date":"2023-08-18","current":-2.35532,"twenty":-8.735869,"median":-4.904886,"eighty":-1.50685,"marketCap":99483990},{"date":"2023-08-25","current":-2.339512,"twenty":-8.649934,"median":-4.879071,"eighty":-1.50685,"marketCap":98816312},{"date":"2023-09-01","current":-2.371127,"twenty":-8.539552,"median":-4.870065,"eighty":-1.50685,"marketCap":100151668},{"date":"2023-09-08","current":-2.181437,"twenty":-8.281298,"median":-4.838504,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-15","current":-2.181437,"twenty":-7.808558,"median":-4.797468,"eighty":-1.50685,"marketCap":92139535},{"date":"2023-09-22","current":-2.118207,"twenty":-7.690618,"median":-4.694622,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-09-29","current":-2.023362,"twenty":-7.570553,"median":-4.543378,"eighty":-1.50685,"marketCap":85462757},{"date":"2023-10-06","current":-1.944324,"twenty":-7.460249,"median":-4.47683,"eighty":-1.50685,"marketCap":82124368},{"date":"2023-10-13","current":-1.896902,"twenty":-7.296875,"median":-4.400739,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-10-20","current":-2.118207,"twenty":-7.080972,"median":-4.345558,"eighty":-1.50685,"marketCap":89468823},{"date":"2023-10-27","current":-1.786249,"twenty":-6.897329,"median":-4.267384,"eighty":-1.50685,"marketCap":75447590},{"date":"2023-11-03","current":-1.849479,"twenty":-6.768204,"median":-4.253588,"eighty":-1.50685,"marketCap":78118301},{"date":"2023-11-10","current":-5.023281,"twenty":-6.674971,"median":-4.240889,"eighty":-1.50685,"marketCap":80121334},{"date":"2023-11-17","current":-8.487937,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":86415686},{"date":"2023-11-24","current":-8.948523,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":91104909},{"date":"2023-12-01","current":-9.145917,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":93114576},{"date":"2023-12-08","current":-9.606502,"twenty":-6.671374,"median":-4.24264,"eighty":-1.50685,"marketCap":97803799},{"date":"2023-12-15","current":-9.6723,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":98473688},{"date":"2023-12-22","current":-9.277512,"twenty":-6.669198,"median":-4.240889,"eighty":-1.50685,"marketCap":94454354},{"date":"2023-12-29","current":-10.165785,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":103497856},{"date":"2024-01-05","current":-10.198684,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":103832801},{"date":"2024-01-12","current":-11.119855,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":113211247},{"date":"2024-01-19","current":-11.054057,"twenty":-6.64075,"median":-4.231182,"eighty":-1.50685,"marketCap":112541358},{"date":"2024-01-26","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-02","current":-10.067088,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":102493023},{"date":"2024-02-09","current":-9.606502,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":97803799},{"date":"2024-02-16","current":-9.869694,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":100483356},{"date":"2024-02-23","current":-9.738098,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":99143577},{"date":"2024-03-01","current":-16.1205,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":164122814},{"date":"2024-03-08","current":-16.844278,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":171491594},{"date":"2024-03-15","current":-245.178585,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":139506615},{"date":"2024-03-22","current":-266.601956,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":151696513},{"date":"2024-03-28","current":-260.689917,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":148332563},{"date":"2024-04-05","current":-245.215172,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":139527433},{"date":"2024-04-12","current":-255.928457,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":145623292},{"date":"2024-04-19","current":-205.93313,"twenty":-6.649081,"median":-4.236368,"eighty":-1.50685,"marketCap":117175951},{"date":"2024-04-26","current":-190.458387,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":108370822},{"date":"2024-05-03","current":-535.664214,"twenty":-6.658855,"median":-4.238628,"eighty":-1.50685,"marketCap":304792938},{"date":"2024-05-10","current":8.357394,"twenty":-6.64746,"median":-4.217605,"eighty":-1.472316,"marketCap":138172798},{"date":"2024-05-17","current":8.193524,"twenty":-6.64746,"median":-4.155757,"eighty":-1.455856,"marketCap":135463528},{"date":"2024-05-24","current":8.624717,"twenty":-6.64746,"median":-4.086161,"eighty":-1.44458,"marketCap":142592445},{"date":"2024-05-31","current":8.24768,"twenty":-6.64746,"median":-4.078366,"eighty":-1.425186,"marketCap":136358895},{"date":"2024-06-07","current":7.870643,"twenty":-6.64746,"median":-4.044422,"eighty":-1.381595,"marketCap":130125346},{"date":"2024-06-14","current":6.880922,"twenty":-6.649081,"median":-4.02817,"eighty":-1.363555,"marketCap":113762278},{"date":"2024-06-21","current":6.032589,"twenty":-6.650702,"median":-3.970254,"eighty":-1.332765,"marketCap":99736792},{"date":"2024-06-28","current":5.93833,"twenty":-6.658855,"median":-3.954687,"eighty":-1.325927,"marketCap":98178404},{"date":"2024-07-05","current":6.126848,"twenty":-6.658855,"median":-3.93891,"eighty":-1.323047,"marketCap":101295179},{"date":"2024-07-12","current":6.598144,"twenty":-6.653992,"median":-3.9179,"eighty":-1.302891,"marketCap":109087116},{"date":"2024-07-15","current":6.692403,"twenty":-6.653992,"median":-3.9179,"eighty":-1.298362,"marketCap":110645503},{"date":"2024-08-02","current":6.315366,"twenty":-6.689358,"median":-3.816355,"eighty":-1.266142,"marketCap":104411954},{"date":"2024-08-09","current":8.314881,"twenty":-6.689358,"median":-3.774712,"eighty":-1.247243,"marketCap":92178769},{"date":"2024-08-16","current":8.385346,"twenty":-6.689358,"median":-3.738504,"eighty":-1.230576,"marketCap":92959945},{"date":"2024-08-23","current":8.385346,"twenty":-6.689358,"median":-3.711348,"eighty":-1.212085,"marketCap":92959945},{"date":"2024-08-30","current":8.103486,"twenty":-6.689358,"median":-3.684192,"eighty":-1.202123,"marketCap":89835241},{"date":"2024-09-06","current":8.314881,"twenty":-6.689358,"median":-3.65026,"eighty":-1.178228,"marketCap":92178769},{"date":"2024-09-13","current":8.808136,"twenty":-6.689358,"median":-3.616096,"eighty":-1.164056,"marketCap":97647001},{"date":"2024-09-20","current":8.244416,"twenty":-6.689358,"median":-3.581932,"eighty":-1.153624,"marketCap":91397593},{"date":"2024-09-27","current":8.455811,"twenty":-6.689358,"median":-3.549144,"eighty":-1.151142,"marketCap":93741121},{"date":"2024-10-04","current":7.962555,"twenty":-6.689358,"median":-3.547642,"eighty":-1.145218,"marketCap":88272889},{"date":"2024-10-11","current":7.89209,"twenty":-6.689358,"median":-3.547642,"eighty":-1.138105,"marketCap":87491713},{"date":"2024-10-18","current":8.173951,"twenty":-6.689358,"median":-3.547642,"eighty":-1.133619,"marketCap":90616417},{"date":"2024-10-25","current":7.61023,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123879,"marketCap":84367009},{"date":"2024-10-31","current":6.990137,"twenty":-6.689358,"median":-3.547642,"eighty":-1.123212,"marketCap":77492660},{"date":"2024-11-08","current":5.648417,"twenty":-6.689382,"median":-3.557463,"eighty":-1.116693,"marketCap":78117601},{"date":"2024-11-15","current":5.658632,"twenty":-6.689382,"median":-3.557463,"eighty":-1.109597,"marketCap":78258879},{"date":"2024-11-22","current":4.903204,"twenty":-6.689382,"median":-3.557463,"eighty":-1.103501,"marketCap":67811318},{"date":"2024-11-29","current":5.99815,"twenty":-6.689382,"median":-3.557463,"eighty":-1.100278,"marketCap":82954411},{"date":"2024-12-06","current":6.564013,"twenty":-6.689382,"median":-3.557463,"eighty":-1.089994,"marketCap":90780299},{"date":"2024-12-13","current":6.337668,"twenty":-6.689382,"median":-3.557463,"eighty":-1.088313,"marketCap":87649944},{"date":"2024-12-20","current":6.224495,"twenty":-6.689382,"median":-3.524056,"eighty":-1.083428,"marketCap":86084766},{"date":"2024-12-27","current":6.394254,"twenty":-6.689382,"median":-3.50315,"eighty":-1.075266,"marketCap":88432533},{"date":"2025-01-03","current":5.99815,"twenty":-6.689382,"median":-3.466942,"eighty":-1.066973,"marketCap":82954411},{"date":"2025-01-10","current":5.561303,"twenty":-6.689406,"median":-3.432284,"eighty":-1.062686,"marketCap":76912826},{"date":"2025-01-17","current":4.793427,"twenty":-6.689406,"median":-3.407046,"eighty":-1.052912,"marketCap":66293096},{"date":"2025-01-24","current":4.910561,"twenty":-6.689406,"median":-3.383641,"eighty":-1.045009,"marketCap":67913055},{"date":"2025-01-31","current":4.951303,"twenty":-6.689406,"median":-3.339237,"eighty":-1.04102,"marketCap":68476519},{"date":"2025-02-07","current":4.92301,"twenty":-6.689406,"median":-3.312429,"eighty":-1.030008,"marketCap":68085224},{"date":"2025-02-14","current":4.675727,"twenty":-6.689406,"median":-3.262613,"eighty":-1.023149,"marketCap":64665311},{"date":"2025-02-21","current":4.618009,"twenty":-6.689406,"median":-3.171091,"eighty":-1.017181,"marketCap":63867071},{"date":"2025-02-28","current":3.820708,"twenty":-6.689406,"median":-2.946017,"eighty":-1.014294,"marketCap":52840395},{"date":"2025-03-07","current":3.493073,"twenty":-6.68943,"median":-2.758827,"eighty":-1.008519,"marketCap":48309206},{"date":"2025-03-14","current":1.484923,"twenty":-6.68943,"median":-2.592432,"eighty":-0.997777,"marketCap":47323014},{"date":"2025-03-21","current":1.67368,"twenty":-6.68943,"median":-2.592432,"eighty":-0.993872,"marketCap":53338516},{"date":"2025-03-28","current":1.549769,"twenty":-6.68943,"median":-2.38569,"eighty":-0.983881,"marketCap":49389591},{"date":"2025-04-04","current":1.365033,"twenty":-6.68943,"median":-2.35532,"eighty":-0.968301,"marketCap":43502249},{"date":"2025-04-11","current":1.243133,"twenty":-6.689406,"median":-2.315801,"eighty":-0.959836,"marketCap":39617405},{"date":"2025-04-17","current":1.582695,"twenty":-6.689406,"median":-2.277053,"eighty":-0.953028,"marketCap":50438900},{"date":"2025-04-25","current":1.92477,"twenty":-6.68943,"median":-2.181437,"eighty":-0.913887,"marketCap":61340494},{"date":"2025-05-01","current":1.870732,"twenty":-6.68943,"median":-2.165629,"eighty":-0.901293,"marketCap":59618347}],"updateTime":1746205406292}}}